Skip to content

Activating regulatory intelligence with AI

April 28, 2026

3:00 PM GMT / 10:00 AM EST

Virtual

Regulatory Intelligence Forum about how teams are increasingly using AI to turn insight into confident action. As regulatory teams face growing pressure in 2026 to apply AI more effectively, many are still working through how to do this with confidence and control. Our latest Regulatory Forum brings together Jill Lee from Novo Nordisk and other industry leaders to share how they’re approaching AI use in practice, building accountability, and supporting coordinated action.

Infodesk logo

Applying AI without losing accountability

Across life sciences, regulatory teams are under pressure to use AI more effectively, without compromising diligence or defensibility. Monitoring alone is no longer enough. What matters is how intelligence is curated, assessed, and translated into action across the regulatory value chain.

Based on findings from an Infodesk 2025 customer survey, this Regulatory Forum explores how teams involved in regulatory intelligence, regulatory affairs, quality assurance, GxP, and pharmacovigilance are approaching AI use to strengthen performance in 2026.

This is a peer-led discussion focused on practical approaches, real constraints, and informed caution.

Team of professionals talking in an office and looking at a laptop

What the forum will explore

  • How AI is being adopted across regulatory intelligence and the wider regulatory ecosystem.
  • How regulators and authorities themselves are using AI and what that means for industry.
  • Practical AI use cases across monitoring, curation, refinement, and downstream activation.
  • How teams are approaching AI skills development, including prompt writing and agent-based tools.
  • Where AI adds value today, and where human judgment is still required.

Forum hosts

Jill Lee

Senior Director, Regulatory Policy & Intelligence at Novo Nordisk Inc.

Jill Lee is Senior Director of Regulatory Policy & Intelligence at Novo Nordisk Inc., where she leads US regulatory policy development and intelligence. In this role, she focuses on FDA policy and engagement, internal compliance, and cross‑functional stakeholder collaboration, translating complex regulatory landscapes into actionable insights for the organization. Jill has over 18 years of industry experience and began her career providing regulatory legal support for medical devices and pharmaceuticals. Jill holds a JD from Rutgers University and a BA from Mary Washington University.

Corina Posey

Leader in Global Quality Compliance at Vertex Pharmaceuticals

Corina is a quality systems leader with Vertex, a global leader in developing transformative therapies for people with serious diseases. She is responsible for ensuring that products meet the highest standards of safety, efficacy, and compliance with regulatory requirements. Corina has over twenty years’ experience in the pharmaceutical industry with an MBA in Health Care Administration.

Chris Whalley

Sr. Director and Head of Global Regulatory Intelligence & Analysis

Chris leads regulatory intelligence activities across Pfizer. A new medicine veteran with 25 years’ experience building regulatory affairs and intelligence solutions that accelerate the delivery of novel drugs and devices to patients. Chris leads the team who deliver actionable insights for regulatory strategists, advancing product development and lifecycle with reduced time to market. Chris is the current Chair of RAPS Regulatory Convergence Planning Committee and the Recipient of RAPS Community Leadership Award 2023.

Team of professionals working together

Who should take part

This forum is relevant to professionals involved in regulatory decision-making and downstream impact across life sciences, including:

  • Regulatory intelligence and regulatory affairs teams
  • Quality assurance and GxP functions
  • Pharmacovigilance teams
  • Anyone responsible for assessing regulatory impact and coordinating downstream action
Man and woman smiling at a laptop

What you’ll take away

By the end of the session, you’ll leave with a clearer view of how peers are:

  • Using AI with more confidence and control.
  • Embedding intelligence into real workflows, not side tools.
  • Balancing efficiency with defensibility and audit readiness.
  • Identifying practical next steps for 2026, grounded in real experience.

You’ll also be invited to complete a short self-assessment after the event, designed to help regulatory teams understand where they stand today and what actions could strengthen their approach. The assessment generates a free report with a clear summary of findings and recommended actions.

Previous forums

See insights from previous regulatory forums